To address this gap, herein, we present two cases of patients with metastatic CDC expressing high levels of PD-L1, c-MET, and AXEL, who exhibited favorable responses to nivolumab and cabozantinib combination therapy. The gene discussed is MET; the disease is collecting duct carcinoma.